Table 5.

Secondary analysis of the incidence rate ratio (IRR) of emergency department (ED) visits and hospitalizations for hydroxychloroquine (HCQ) and immunosuppressive (IS) nonadherers at two levels (MPR 0–49% and 50–79%) compared to adherers (MPR ≥80%)

		ED Visits IRR* (95% CI)		Hospitalizations IRR* (95% CI)
		All-Cause	SLE-related	All-Cause	SLE-related
HCQ	MPR 0–49%	1.71 (1.57–1.86)	1.75 (1.56–1.97)	1.50 (1.36–1.65)	1.43 (1.29–1.58)
	MPR 50–79%	1.26 (1.14–1.39)	1.31 (1.15–1.50)	1.13 (1.01–1.26)	1.07 0.95–1.21)
IS	MPR 0–49%	1.42 (1.26–1.59)	1.71 (1.40–2.09)	1.75 (1.48–2.07)	1.65 (1.38–1.98)
	MPR 50–79%	1.18 (1.04–1.34)	1.62 (1.30–2.03)	1.47 (1.21–1.77)	1.48 (1.20–1.81)

^*Incidence Rate Ratios (IRR) compare each nonadherence category (MPR 0–49% and MPR 50–79%) to adherers (MPR ≥80%) with 95% confidence intervals. Poisson regression models adjusted for calendar year, age, gender, race/ethnicity, geographic region, socioeconomic status, SLE risk-adjustment index and baseline number of medications.